Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. by Hsiang, Michelle S et al.
Articles
www.thelancet.com   Vol 395   April 25, 2020 1361
Effectiveness of reactive focal mass drug administration and 
reactive focal vector control to reduce malaria transmission 
in the low malaria-endemic setting of Namibia: 
a cluster-randomised controlled, open-label, two-by-two 
factorial design trial
Michelle S Hsiang*, Henry Ntuku*, Kathryn W Roberts, Mi-Suk Kang Dufour, Brooke Whittemore, Munyaradzi Tambo, Patrick McCreesh, 
Oliver F Medzihradsky, Lisa M Prach, Griffith Siloka, Noel Siame, Cara Smith Gueye, Leah Schrubbe, Lindsey Wu, Valerie Scott, Sofonias Tessema, 
Bryan Greenhouse, Erica Erlank, Lizette L Koekemoer, Hugh J W Sturrock, Agnes Mwilima, Stark Katokele, Petrina Uusiku, Adam Bennett, 
Jennifer L Smith, Immo Kleinschmidt†, Davis Mumbengegwi†, Roly Gosling†
Summary
Background In low malaria-endemic settings, screening and treatment of individuals in close proximity to index 
cases, also known as reactive case detection (RACD), is practised for surveillance and response. However, other 
approaches could be more effective for reducing transmission. We aimed to evaluate the effectiveness of reactive focal 
mass drug administration (rfMDA) and reactive focal vector control (RAVC) in the low malaria-endemic setting of 
Zambezi (Namibia).
Methods We did a cluster-randomised controlled, open-label trial using a two-by-two factorial design of 
56 enumeration area clusters in the low malaria-endemic setting of Zambezi (Namibia). We randomly assigned 
these clusters using restricted randomisation to four groups: RACD only, rfMDA only, RAVC plus RACD, or rfMDA 
plus RAVC. RACD involved rapid diagnostic testing and treatment with artemether-lumefantrine and single-dose 
primaquine, rfMDA involved presumptive treatment with artemether-lumefantrine, and RAVC involved indoor 
residual spraying with pirimiphos-methyl. Interventions were administered within 500 m of index cases. To evaluate 
the effectiveness of interventions targeting the parasite reservoir in humans (rfMDA vs RACD), in mosquitoes 
(RAVC vs no RAVC), and in both humans and mosquitoes (rfMDA plus RAVC vs RACD only), an intention-to-treat 
analysis was done. For each of the three comparisons, the primary outcome was the cumulative incidence of locally 
acquired malaria cases. This trial is registered with ClinicalTrials.gov, number NCT02610400.
Findings Between Jan 1, 2017, and Dec 31, 2017, 55 enumeration area clusters had 1118 eligible index cases that led to 
342 interventions covering 8948 individuals. The cumulative incidence of locally acquired malaria was 30·8 per 
1000 person-years (95% CI 12·8–48·7) in the clusters that received rfMDA versus 38·3 per 1000 person-years 
(23·0–53·6) in the clusters that received RACD; 30·2 per 1000 person-years (15·0–45·5) in the clusters that received 
RAVC versus 38·9 per 1000 person-years (20·7–57·1) in the clusters that did not receive RAVC; and 25·0 per 
1000 person-years (5·2–44·7) in the clusters that received rfMDA plus RAVC versus 41·4 per 1000 person-years 
(21·5–61·2) in the clusters that received RACD only. After adjusting for imbalances in baseline and implementation 
factors, the incidence of malaria was lower in clusters receiving rfMDA than in those receiving RACD (adjusted 
incidence rate ratio 0·52 [95% CI 0·16–0·88], p=0·009), lower in clusters receiving RAVC than in those that did not 
(0·48 [0·16–0·80], p=0·002), and lower in clusters that received rfMDA plus RAVC than in those receiving RACD 
only (0·26 [0·10–0·68], p=0·006). No serious adverse events were reported.
Interpretation In a low malaria-endemic setting, rfMDA and RAVC, implemented alone and in combination, reduced 
malaria transmission and should be considered as alternatives to RACD for elimination of malaria.
Funding Novartis Foundation, Bill & Melinda Gates Foundation, and Horchow Family Fund.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Successes achieved through malaria control efforts 
have inspired many countries to set goals to interrupt 
domestic parasite transmission.1 However, progress 
towards eliminating malaria in southern Africa and 
worldwide has slowed, highlighting the need for new 
approaches.1 Compared with moderate and high malaria 
transmission settings, malaria infections cluster by 
location and time in low malaria trans mission settings, 
and a higher proportion of infections are low-density 
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and asymptomatic.2,3 Focal screening and treatment of 
indi viduals in the immediate vicinity of passively 
detected cases—a strategy known as reactive case 
detection (RACD)—is a widely practised response for 
reducing transmission and increasing surveil lance. 
However, the effectiveness of this strategy is limited by 
the low sensitivity of point-of-care tests in detecting low-
density chronic infections that perpetuate transmis-
sion.4–6 As such, WHO does not recommend RACD for 
interrupting malaria transmission with the diagnostic 
tests that are currently available.7
Mass drug administration (MDA), or antimalarial drug 
administration without previous malaria testing, is 
recommended by WHO for eliminating malaria caused 
by Plasmodium falciparum if there is reliable access to case 
management, effective vector control and surveillance, 
and if there is minimal risk of reintroduction of infec-
tion.7 MDA targets the parasite reservoir in humans, 
and the effects of MDA on parasite prevalence can be 
observed beyond 1 year in settings with accompanying 
vector control, low levels of transmission, and little 
malaria importation.8,9 Chal lenges for successful imple-
mentation of MDA include achieving high population 
coverage, accept ability, and adherence, high costs, safety, 
and establishing adequate pharma covigilance.8,10 Targeted 
drug administration to smaller populations of people 
who are at higher risk of malaria, known as focal MDA 
(fMDA), can mitigate some of these challenges. Reactive 
focal mass drug administration (rfMDA), defined as 
MDA targeting household mem bers and neighbours of 
recent passively detected cases, targets only those at 
highest risk of infection11 and utilises existing RACD 
Research in context
Evidence before this study
On Sept 4, 2019, we searched PubMed for original articles 
using the search terms “mass drug administration OR indoor 
residual spraying” AND “focal OR targeted OR reactive OR 
outbreak OR reduce transmission OR interrupt transmission OR 
malaria elimination” AND “Plasmodium falciparum OR malaria”, 
with no restrictions on language or time period. We reviewed 
578 titles and abstracts and found six cluster-randomised 
controlled trials (four in Africa and two in Asia) in which focal 
mass drug administration (fMDA) was targeted to individuals 
at the village level or to groups of households in low 
transmission settings. In Kenya, fMDA with artemether-
lumefantrine combined with several vector control 
interventions (indoor residual spraying, long-lasting 
insecticidal nets, and larvaciding) resulted in a modest (10%) 
decrease in the prevalence of malaria in areas that received the 
intervention directly, but no broader community effects were 
observed. In Tanzania, the effect of one round of sulphadoxine–
pyrimethamine, artesunate plus single-dose primaquine could 
not be assessed because of the near absence of malaria 
detected in control and intervention clusters during a 5-month 
follow-up period. Another study in Zambia, in which vector 
control interventions (indoor residual spraying and long-
lasting insecticidal nets) were implemented at baseline, 
fMDA with dihydroartemisinin–piperaquine—a drug that has a 
longer half-life than artemether–lumefantrine—reduced the 
prevalence of malaria by 87% and the incidence by 70% in 
lower transmission areas (ie, areas with a baseline prevalence 
of <10%) when compared with no fMDA. In The Gambia, 
annual dihydroartemisinin–piperaquine administration 
reduced clinical malaria incidence by 50% over 2 years. 
After establishing vector control and a community-based case 
management system, one multisite trial in Myanmar, Vietnam, 
Cambodia, and Laos showed that three monthly rounds of 
dihydroartemisinin–piperaquine reduced the incidence of 
Plasmodium falciparum malaria by 59% and the prevalence by 
46% when compared with control. In Cambodia, three rounds 
of dihydroartemisinin-piperaquine administration decreased 
the incidence of malaria by 94% after 1 year compared with 
control, and in a subsequent follow-up year, there were no 
clinical cases of P falciparum malaria. All identified trials were 
limited by small sample sizes (2–10 clusters per study arm) and 
the inability to distinguish the effect of drug-based versus 
concurrently administered vector control interventions. We did 
not find any studies of reactive fMDA (rfMDA). Studies of focal 
indoor residual spraying were similarly limited to those in 
which this intervention was applied before the transmission 
season, and there were no controlled studies of this 
intervention.
Added value of this study
Our study is the first trial to evaluate MDA and vector control 
strategies implemented in a reactive and focal approach. 
Our study is also the first to evaluate the individual and 
combined effects of MDA and vector control strategies on 
malaria transmission reduction. In a low malaria-endemic 
setting, where there was high baseline coverage of preseason 
indoor residual spraying and a low frequency of malaria 
importation, rfMDA (presumptive treatment with artemether–
lumefantrine) administered over one malaria transmission 
season reduced malaria incidence by 48% and prevalence by 
41% compared with RACD, and reactive focal vector control 
(RAVC; indoor residual spraying with pirimiphos-methyl) 
administered over one transmission season reduced malaria 
incidence by 52% and prevalence by 64% compared with no 
RAVC. When combined, rfMDA and RAVC reduced malaria 
incidence by 74% and prevalence by 84% compared with RACD 
only. All interventions were safe and community participation 
was high.
Implications of all the available evidence
When administered alone and in combination, rfMDA and 
RAVC are effective and safe strategies that should be considered 
as part of a comprehensive malaria elimination programme.
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infrastructure. rfMDA could be appro priate in malaria 
elimination settings, but evidence from randomised 
controlled trials that supports this notion is absent.12
Malaria vector control with long-lasting insecticidal 
nets or preseason indoor residual spraying in entire 
communities (ie, blanket approaches) have been the 
primary drivers for reducing the number of malaria 
cases and deaths in sub-Saharan Africa since 2000.13 
In many low malaria-endemic countries, indoor residual 
spraying is the primary method of malaria prevention.14,15 
However, IRS campaigns often do not achieve adequate 
high quality insecticide application coverage because 
of logistical challenges in training, organising, and 
supervising seasonal spray personnel, and because of the 
rising costs of effective insecticides.15 Emerging insec-
ticide resistance, the short-term effects of indoor residual 
spraying (often only 2–6 months), and residual or 
outdoor transmission that is not controlled by indoor 
residual spraying, pose challenges for current vector 
control strategies.12,16 A highly effective but expensive new 
organophosphorus insecticide formulation, pirimiphos-
methyl,17 has been shown to be effective for up to 
12 months.18 Reactive focal use of this new insecticide as 
an adjunct to preseason indoor residual spraying could 
be particularly effective in reducing the mosquito parasite 
reservoir while keeping costs low.12
Since 2016, there have been outbreaks of malaria 
in northern Namibia, despite the implementation of 
RACD since 2012 and the widespread application of 
indoor residual spraying14 for several decades.19,20 To 
accelerate malaria elimination in Namibia and other 
low transmission settings, new approaches are needed. 
We did a cluster-randomised controlled, open-label 
trial with a two-by-two factorial design to evaluate the 
effectiveness, safety, and operational feasibility of two 
reactive focal malaria interventions, each used alone or 
in combination, to reduce the incidence of malaria and 
the prevalence of infection: rfMDA, which targets the 
parasite in humans, and reactive focal vector control 
(RAVC) with indoor residual spraying of pirimiphos-
methyl, which targets the vector.
Methods
Study design and participants
We did a four-group cluster-randomised controlled, 
open-label trial using a two-by-two factorial design. The 
trial protocol has been published previously.21
The study was done between Jan 1, 2017, and Dec 31, 2017. 
The study site was the Zambezi region of northern 
Namibia, encompassing 11 health facility catchment areas 
(appendix p 2) with an enumerated population of 33 418.21 
Malaria transmission in this region is seasonal, with the 
incidence peaking from January to June. Malaria is almost 
entirely caused by P falciparum, with an annual incidence 
of less than 15 cases per 1000 individuals since 2010, 
increasing to 32·5 cases per 1000 individuals in 2016 
following an outbreak.19–21 The community-level prevalence 
of infection, measured by loop-mediated isothermal 
amplification, was 2·2% in 2015.22 Routine interventions 
administered by the Namibia Ministry of Health and 
Social Services include case management, RACD, and 
annual preseason blanket indoor residual spraying of 
households with dichlorodiphenyltrichloroethane (DDT), 
except for a minority of modern structures that are 
sprayed with deltamethrin.20 These interventions, apart 
from RACD, which were not used in the rfMDA study 
arms, were continued during the study. Study health-
care facilities were visited to collect data from patient 
registers about confirmed malaria cases and to establish 
an electronic system for the rapid geolocated reporting of 
cases. A geographical reconnaissance census was done to 
enumerate and geolocate all households in the study area. 
Sensitisation activities with community leaders, health 
workers, and villagers were also done before the study.21 
The study period was originally intended to be 2 years, 
however, the malaria outbreak in 2016, for which the team 
was not prepared, resulted in incomplete intervention 
imple mentation and data capture. Therefore, data from 
2016 were not analysed. After increasing the number of 
staff and re-randomising the clusters, the trial was 
re-launched in 2017.
Census enumeration areas (clusters) were randomly 
assigned to receive rfMDA (presumptive treatment with 
artemether-lumefantrine) or RACD (rapid diagnostic 
testing and treatment with artemether-lumefantrine and 
single-dose primaquine), with or without additional 
RAVC (reactive focal indoor residual spraying with 
pirimiphos-methyl). By use of a two-by-two factorial 
design (figure 1), the effectiveness of three interventions 
were compared with three respective controls: (1) rfMDA 
versus RACD (B and D vs A and C); (2) RAVC versus no 
See Online for appendix
Figure 1: Two-by-two factorial study design of reactive focal interventions
Reactive case detection involved administering rapid diagnostic tests for malaria to 
individuals living within a 500-m radius of an index case, and treating individuals 
who tested positive with artemether-lumefantrine and single-dose primaquine. 
Reactive focal mass drug administration involved presumptively treating 
individuals living within a 500-m radius of an index case with artemether-
lumefantrine, without testing for malaria beforehand. Reactive focal vector control 
involved spraying the long-lasting insecticide, pirimiphos-methyl, to the interior 
walls of households located within a seven-household radius of an index case. 
The effectiveness of three interventions were compared to three respective 
controls: (1) rfMDA versus RACD (B and D vs A and C); (2) RAVC versus no RAVC 
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RAVC (C and D vs A and B); and (3) rfMDA plus RAVC 
versus RACD only (D vs A). Enumeration areas were 
eligible for inclusion if they were located within the 
catchment area of one of the 11 study health-care facilities. 
Enumeration areas that had no reported incident cases or 
incomplete incidence data from 2012–14 were excluded.
Passively detected index cases, confirmed by rapid 
diagnostic tests or microscopy, irrespective of origin 
(ie, local or imported), were eligible to trigger an 
intervention if they were confirmed to have resided in or 
have stayed for at least one night in a study enumeration 
area in the previous 4 weeks. Populations residing 
within 500 m of the index case were eligible to receive 
reactive inter ventions, according to the group to which 
their enumeration area was randomly assigned.5,23 
Individuals were excluded if they: refused to participate; 
had received non-study indoor residual spraying in the 
previous 24 h; had been given artemether-lumefantrine 
in the previous 5 weeks in a study intervention; were 
reported to be pregnant or had a positive pregnancy test; 
had amenorrhoea for 4 weeks despite previous regular 
menses and refused to take a pregnancy test; weighed 
less than 5 kg; were aged less than 6 months; had severe 
malaria; had an allergy to artemether-lumefantrine; and 
had a history of cardiac dysrhythmia, or a known family 
history of long QT syndrome and were current users of 
QT-prolonging medications. Interventions were not 
repeated in areas that had received an intervention in 
the previous 5 weeks (rfMDA or RACD) or during the 
most recent malaria season (RAVC). More infor mation 
about the study inclusion and exclusion criteria can be 
found in the appendix (p 3).
The trial received ethical approval from the Namibia 
Ministry of Health and Social Services (17/3/3), and the 
Institutional Review Boards of the University of Namibia 
(MRC/259/2017), University of California San Francisco 
(15–17422) and London School of Hygiene & Tropical 
Medicine (10411). Written informed consent was obtained 
from individual participants for rfMDA or RACD, and 
from heads of households (≥18 years of age) for RAVC. 
A parent or guardian was required to provide written 
informed consent for children younger than 18 years 
receiving rfMDA or RACD, and written consent for 
receiving these interventions was also obtained from 
children aged 12–17 years.
Randomisation and masking
Of 102 candidate enumeration areas, 46 met the exclu-
sion criteria of no incident cases of malaria between 
2012 and 2014 or incomplete incidence data due to 
missing records. We randomly assigned the remaining 
56 clusters to one of four arms (RACD only, RACD plus 
RAVC, rfMDA only, or rfMDA plus RAVC [figure 2 
and appendix p 2]) using restricted randomisation to 
ensure balance between study arms.24 Restriction criteria 
were as follows: mean annual incidence in 2013 and 
2014, population size, population density, and mean 
distance from the household to a health-care facility, 
which was used a measure of access to health-care. 
Incidence data for 2015 were not available,21 and data 
from 2016 were anomalous because of the malaria out-
break19 and were therefore not included. 100 000 assign-
ments that met the restriction criteria were randomly 
generated by the study statistician, and the final allocation 
was randomly selected by the Namibia Ministry of Health 
and Social Services. Because of a limited number of 
available clusters, buffer zones could not be included. 
The nature of the interventions made masking imprac-
tical for field activities, however, labo ratory analyses were 
done blinded.
Procedures
Once reported, index cases were geolocated by use of 
unique household barcodes placed in health passports 
and household doorframes during the geographical 
reconnaissance survey, or on the basis of the reported 
village of residence. A centralised spatial decision support 
system25 was used to maximise coverage and minimise 
travel times for field teams, and to prioritise cases that 
resulted in death or were from areas with a higher recent 
case burden while still ensuring that at least one case 
from each intervention arm was covered each week (more 
information about how index cases were prioritised is 
detailed in the appendix p 4). Field teams aimed to visit 
the household of the index case and eligible neighbouring 
households within 7 days to 5 weeks from the time of 
reporting, and households closest to the index case 
were prioritised. To cover 80% or more of individuals 
or households within 500 m of index cases,5,8,23 field 
teams aimed to deliver RACD (rapid diagnostic testing 
and treatment with artemether-lumefantrine and single-
dose primaquine [Coartem, Novartis Pharmaceuticals, 
Kempton Park, South Africa; or Komefan 140, Mylan 
Laboratories, Sinnar, India]; appendix p 5) and rfMDA 
(presumptive treatment with artemether-lumefantrine 
[appendix p 5]) to at least 25 individuals, and RAVC 
(reactive focal indoor resi dual spraying with pirimiphos-
methyl [Actellic 300CS, Syngenta, Basel, Switzerland]), if 
indicated, to at least seven households. The teams made 
one follow-up visit on a different date and time from the 
first visit, if needed. Although the number of individuals 
or households within a 500-m radius could vary according 
to population density, these target numbers provided a 
practical guide for field operations. Six teams admin-
istered RACD or rfMDA and three teams administered 
RAVC, with each team consisting of three staff members. 
Additional staff made supervisory visits to ensure that 
protocols for field interventions and health-care facility-
based case manage ment and reporting were followed.
For clusters assigned to receive RACD, consenting 
individuals received rapid diagnostic tests for malaria 
and a dried blood spot was collected for later laboratory 
testing. According to Namibia Ministry of Health and 
Social Services policy, participants who tested positive for 
Articles
www.thelancet.com   Vol 395   April 25, 2020 1365
Figure 2: Trial profile
RACD=reactive case detection. RAVC=reactive vector control. rfMDA=reactive focal mass drug administration. AL=artemether-lumefantrine. RDT=rapid diagnostic test. *Eligible cases were not 
covered because the study team was unable to respond within 5 weeks of the index case being reported because of a high case load.
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malaria received artemether-lumefantrine and a single 
dose of primaquine (0·25 mg/kg; Primaquine, Remedica, 
Cyprus) orally. For clusters assigned to receive rfMDA, 
consenting individuals received artemether-lumefantrine 
only. All first doses of artemether-lumefantrine were 
directly administered and participants were given 
instructions for subsequent doses. Individuals with 
contraindications to artemether-lumefantrine had a rapid 
diagnostic test and a dried blood spot sample was 
collected. If these individuals tested positive for malaria, 
they were referred to the nearest health-care facility, as 
were participants with suspected severe malaria or those 
who required medical attention. In clusters randomly 
assigned to receive RAVC, the ceilings and walls of 
sleeping structures in consenting households were 
sprayed with 300 g/L pirimiphos-methyl with a coverage 
of 1 g/m².26 Because of the high number of malaria index 
cases during the study period, the Namibia Ministry of 
Health and Social Services targeted villages with a high 
disease burden in non-study areas with supplemental 
indoor residual spraying of mainly DDT (a minority of 
modern homes received deltamethrin) in addition to 
routine RACD. For each cluster, the proportion of 
households within 500 m of a village that received an 
intervention administered by the Namibia Ministry of 
Health and Social Services was calculated (coverage data 
were not available). To assess the susceptibility of local 
vectors to insecticides, testing was done according to 
standard WHO protocols (appendix p 6).
Epidemiological data were collected on password-
secured tablets with precoded questionnaires programmed 
in Open Data Kit (version 1.23.3). Pill counts were done 
7–10 days after artemether-lumefantrine treatment was 
initiated in a subsample of participants. Participants were 
instructed to report adverse events to an on-call study 
nurse or to the nearest health-care facility, which then 
notified the study team. Study nurses actively inquired 
about adverse events during follow-up visits. Grading of 
adverse events and establishing causality were done by 
the study physician and reviewed by the Namibia Ministry 
of Health and Social Services Therapeutics Information 
and Pharmacovigilance Centre and the trial Data Safety 
and Monitoring Board.
For the primary outcome, data on confirmed inci-
dent malaria cases, including travel history (to establish 
whether cases were locally acquired or imported), were 
extracted from the rapid reporting system. For the 
secondary outcome of infection prevalence, a cross-sec-
tional survey was done in randomly selected households 
from each enumeration area at the end of the malaria 
season (between May and August) in 2017. Approxi-
mately equal numbers of clusters were sampled from 
each arm each week. Whole blood (approximately 
300 µL) was collected by finger prick for the rapid 
diagnostic test, and dried blood spots and microtainer 
specimens were collected for subsequent molecular 
testing. Individuals who tested positive for malaria were 
treated according to the Namibia Ministry of Health and 
Social Services guidelines.
All rapid diagnostic testing was done with CareStart 
Malaria HRP2/pLDH rapid diagnostic tests (Access Bio, 
Somerset, NJ, USA). Dried blood spots during RACD and 
rfMDA were stored at –20°C before DNA was extracted 
and qualitative molecular detection by loop-mediated 
isother mal amplification with genus-specific primers was 
done, as previously described.27 Whole blood collected in 
the cross-sectional survey was centrifuged and packed red 
blood cells were stored at –20°C before DNA was extracted 
by use of the Quick-DNA Miniprep Kit (Zymo Research 
Corp, Irvine, CA, USA), and quantitative PCR (qPCR) 
targeting the acidic terminal sequence of the var gene28 
was done with DNA extracted from 10 μL of whole blood.
Outcomes
The primary outcome was the cluster-level incidence of 
confirmed malaria cases, acquired locally and detected 
by rapid diagnostic testing or microscopy at health-care 
facilities, 8 weeks after the first intervention was admin-
istered in each cluster. A definition and the rationale for 
the primary outcome is provided in the appendix (p 7).
Secondary outcomes were as follows: the prevalence of 
P falciparum infection, as detected by qPCR, and the 
seroprevalence of the infection, as measured in a cross-
sectional survey done at the end of the malaria season; 
safety, including the number of adverse events, the 
severity, and the proportion of individuals receiving the 
study drug or insecticide, or both, who reported adverse 
events; and measures of operational feasibility, including 
index case coverage (the proportion of eligible index 
cases covered by an intervention), target population or 
household coverage (the proportion of eligible individuals 
or households within an intervention event area that 
received the intervention), acceptability measured as 
refusals (the proportion of eligible individuals or heads 
of households within an intervention event area who 
refused to participate) and focus group discussions, 
adherence (the proportion of individuals participating 
in a pill count who completed the treatment course), 
and cost-effectiveness. Results from the seroprevalence, 
focus group discussions, and cost-effectiveness analyses 
will be reported elsewhere.
Statistical analysis
As elimination of malaria in Namibia is the ultimate aim, 
interventions with large effect sizes, as have been reported 
with MDA and indoor residual spraying, were sought.8,14 
Our study had 80% power to detect a 50% or greater 
relative reduction in incidence in clusters receiving either 
rfMDA or RAVC alone, and to detect a 75% relative 
reduction in incidence in clusters receiving combined 
interventions, with 14 clusters per study arm (harmonic 
mean of 276 individuals per cluster), based on an 
anticipated baseline annual incidence of 24·4 cases per 
1000 individuals for the RACD only arm, a coefficient of 
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variation of 0·95 based on previous incidence (in 2013 and 
2014), and a two-sided significance level of 0·05.24 Allowing 
for index cases already covered by a preceding reactive 
intervention event (10%) and refusals (5%), enrolment of 
a total of 4403 individuals associated with 176 intervention 
events was anticipated. For the cross-sectional survey, 
25 households in each cluster were sampled. Assuming 
a mean household size of four individuals and that 
20% of house holds would not respond to the survey, a 
sample size of 5040 individuals provided 80% power 
to detect a 55% relative reduction in prevalence in 
individuals receiving either rfMDA or RAVC alone, and 
to detect an 83% relative reduction in prevalence in 
those receiving the combined interventions, assuming 
5% prevalence of infection detected by qPCR in the 
RACD only arm, a coefficient of variation of 1·0, and a 
two-sided significance level of 0·05.24
An intention-to-treat approach was used, in which all 
randomised clusters that had incident cases (and 
therefore intervention responses) during the study period 
were included in the analysis. In order to compare 
incident cases that could plausibly be affected by the 
reactive interventions, we excluded incident cases that 
occurred within an 8-week lead-in period that commenced 
from the first intervention response administered within 
each cluster. For the primary outcome, negative binomial 
regression by use of generalised linear models was used 
to estimate incidence rate ratios (IRR) between study 
arms with cluster-level case data and cluster person-time 
as an offset. For the prevalence of infection, log binomial 
regression by use of a log link function was used to 
estimate prevalence ratios (PRs) from individual data 
with generalised estimating equations to adjust for 
enumeration area-level clustering.24 Interaction between 
rfMDA and RAVC was estimated by including an 
appropriate term in the models. As prespecified, baseline 
characteristics (table 1; appendix p 8) that were not already 
included in the restricted randomisation, and for which 
there was an observed imbalance across study arms, were 
first included in the adjusted analysis. To address 
variation in implementation, the adjusted analyses also 
included index case coverage, target population coverage, 
response time, and proximity to co-interventions. To 
assess the relative effects of covariates on outcomes, 
results from models adjusted with 2016 baseline 
incidence only, coverage, response times, and Namibia 
Ministry of Health and Social Services co-interventions 
were generated. No allowance was made for multiplicity 
of statistical significance testing in the analyses. Coverage, 
refusals, adverse events, and adherence were assessed 











 rfMDA plus RAVC 
(n=14 EAs)
Transmission intensity, mean (95% CI)
Number of cases per 
1000 people per year in 2013 
and 2014*
23·5 (16·3–30·6) 23·4 (13·1–33·7) 23·5 (13·0–34·1) 25·5 (14·9–36·1) 21·5 (11·2–31·7) 26·9 (10·8–42·9) 23·0 (7·0–38·9)
Number of cases per 
1000 individuals in 2016
35·9 (21·2–50·5) 29·5 (18·4–40·7) 42·2 (14·3–70·1) 29·5 (14·3–44·8) 42·2 (16·3–68·1) 28·0 (10·5–45·4) 53·3 (1·1–105·5)
Routine interventions, mean (95% CI)
Preseason indoor residual 
spray coverage in 2016
76·8% (70·8–82·7) 77·0% (69·0–85·0) 76·5% (67·2–85·9) 77·7% (68·5–86·9) 75·8% (67·6–84·0) 83·3% (71·8–94·8) 80·9% (68·4–93·5)
Population characteristics, mean (SE)
Cluster size* 336 (16·1) 354 (23·5) 318 (21·9) 334 (21·7) 338 (24·1) 339 (25·9) 308 (26·4)
Distance to nearest 
neighbouring household, m*
45·5 (2·7) 45·3 (3·9) 45·8 (3·7) 48·7 (4·7) 42·4 (2·5) 47·7 (6·9) 42·0 (3·3)
Distance to nearest health-
care facility, km*
5·8 (0·6) 5·4 (0·7) 6·2 (1·0) 4·8 (0·8) 6·8 (0·9) 3·7 (0·8) 6·6 (1·5)
Ecological factors (range)†
Median monthly rainfall 
between November, 2016, 
and April, 2017, mm
23·7 (18·4–26·7) 23·7 (18·4–26·7) 23·3 (18·4–26·7) 23·6 (18·4–26·7) 23·7 (18·4–26·7) 23·4 (18·4–26·7) 23·4 (18·4–26·7)
Median enhanced vegetative 
index between January, 2017, 
and July, 2017
0·16 (0·09–0·31) 0·14 (0·09–0·31) 0·15 (0·09–0·27) 0·14 (0·09–0·22) 0·15 (0·9–0·31) 0·14 (0·10–0·21) 0·15 (0·09–0·27)
Median elevation, m 543 (387–1124) 525 (387–1021) 560 (412–1124) 539 (398–1124) 544 (387–1021) 525 (398–921) 558 (412–984)
Median daytime land surface 
temperature, °C
31·1 (28·6–33·4) 30·6 (28·9–33·4) 31·4 (28·6–32·5) 31·2 (28·6–33·4) 31·1 (28·7–32·5) 30·8 (28·9–33·4) 31·4 (28·7–32·5)
EAs=enumeration areas. RACD=reactive case detection. rfMDA=reactive focal mass drug administration. RAVC=reactive vector control. *Included in the restricted randomisation. †Methods of data collection for 
ecological factors are described in the appendix (p 8).
Table 1: Baseline characteristics
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descriptively. Data were analysed in Stata (version 15) and 
R (version 3.5.0).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Jan 1, 2017, and Dec 31, 2017, 102 enumeration 
area clusters within the study area were assessed for 
eligibility, of which 56 clusters, comprising 18 803 indi-
viduals, met the inclusion criteria for the study. All 
clusters except for one that was randomly assigned to 
receive RACD only, had index cases reported through the 
rapid reporting system, and were included in the analysis 
(figure 2). A total of 1333 index cases were reported. Of 
1118 eligible index cases, 134 (11·7%) were not covered 
because the study team was unable to visit within 5 weeks 
of the index case being reported because of a high case 
load. The demographic characteristics of index cases that 
were not covered were similar to those that were covered 
(appendix p 9). As index cases were clustered by location 
and time, there were 342 intervention events covering 
984 index cases. Among the intervention events, 
5296 individuals were eligible to receive RACD, of whom 
4701 (88·8%) received the intervention and 10 (0·2%) 
refused. 4899 individuals were eligible to receive rfMDA, 
of whom 4247 (86·7%) received the inter vention and 
36 (0·7%) refused. Absence was the most common 
reason for not receiving RACD (492 [9·3%] of 
5296 individuals) and rfMDA (322 [6·6%] of 4899 indi-
viduals). 258 (5·3%) of 4899 individuals did not receive 
rfMDA because artemether-lumefantrine was contra-
indicated. 114 (2%) of 4701 individuals in the RACD study 
arms tested positive according to the rapid diagnostic 
test, and 178 (4%) of 4286 individuals tested positive 
according to loop-mediated isothermal amplification 
(appendix p 10). 1049 households were eligible to 
receive RAVC, of which 937 (89·3%) were sprayed and 
seven (0·7%) refused. Absence was the most common 
known reason for not receiving RAVC (68 [6·5%] of 
1049 households). Base line characteristics across the 
four study arms were well balanced except for pre-
intervention 2016 malaria incidence, which was higher in 
intervention clusters (rfMDA, RAVC, and rfMDA plus 
RAVC) than the control clusters (RACD, no RAVC, and 
RACD only; table 1). Characteristics of index cases and 
individuals receiving study interventions were similar 
across the three com parison groups (appendix pp 11–12). 
On average, 97% of index cases were classified as locally 
acquired.
Cluster-level implementation of each intervention by 
study arm is shown in table 2. The mean index case 
coverage was 84·3% (95% CI 78·4–90·2) for RACD, 
90·8% (85·9–95·8) for rfMDA, and 81·6% (73·4–89·9) 
for RAVC. Mean target population or household coverage 
was 87·1% (83·1–91·1) for RACD, 86·4% (81·7–91·2) for 
rfMDA, 93·3% (90·7–96·0) for RAVC. The median 
intervention response time for all interventions was 
13–14 days (IQR 10–20). Across all comparison groups, 
the mean proportion of households within 500 m of a 











rfMDA plus RAVC 
(n=14 EAs)
RACD coverage
Index case level 84·3% (78·4–90·2) ·· 84·6% (76·0–93·3)* 84·0% (74·8–93·3)† 84·6% (76·0–93·3) ··
Target population level 87·1% (83·1–91·1) ·· 87·5% (81·0–94·0)* 86·8% (81·2–92·4)† 87·5% (81.0–94·0) ··
rfMDA coverage
Index case level ·· 90·8% (85·9–95·8) 93·2% (87·7–98·7)† 88·5% (79·7–97·3)† ·· 88·5% (79·7–97·3)
Target population level ·· 86·4% (81·7–91·2) 85·3% (77·5–93·2)† 87·6% (81·2–94·0)† ·· 87·6% (81·2–94·0)
RAVC coverage
Index case level 80·7% (72·2–89·1)† 82·6% (67·0–98·1)† ·· 81·6% (73·4–89·9) ·· 82·6% (67·0–98·1)
Target household level 91·5% (87·5–95·6)† 95·2% (91·5–98·8)† ·· 93·3% (90·7–96·0) ·· 95·2% (91·5–98·8)
Response time (IQR)‡
Median number of days between reporting of 
index case and the intervention response
14 (10–18) 13 (10–15) 14 (10–20) 13 (10–15) 14 (10–20) 13 (10–15)
Co-interventions
Proportion of households within 500 m of a 
village that received RACD or reactive indoor 
residual spraying, or both, during the study 
period§
55·0% (38·7–71·3) 50·7% (34·2–67·1) 43·4% (27·4–59·4) 61·8% (45·8–77·8) 45·7% (20·7–70·6) 60·0% (35·1–85·0)
Data are mean (95% CI) unless otherwise indicated. RACD=reactive case detection. EAs=enumeration areas. rfMDA=reactive focal mass drug administration. RAVC=reactive vector control. *n=13 EAs. †n=14 EAs. 
‡Response time refers to RACD or rfMDA, as these interventions were implemented first, followed by RAVC. §Indoor residual spraying was done by the Namibia Ministry of Health and Social Services.
Table 2: Cluster-level coverage, response time, and co-interventions by study comparison group
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village that received co-interventions administered by the 
Namibia Ministry of Health and Social Services ranged 
from 43·4% to 61·8%.
The cumulative incidence of locally acquired malaria 
was 30·8 per 1000 person-years (95% CI 12·8–48·7) in 
the clusters that received rfMDA versus 38·3 per 
1000 person-years (23·0–53·6) in the clusters that 
received RACD; 30·2 per 1000 person-years (15·0–45·5) 
in the clusters that received RAVC versus 38·9 per 
1000 person-years (20·7–57·1) in the clusters that did 
not receive RAVC; and 25·0 per 1000 person-years 
(5·2–44·7) in the clusters that received rfMDA plus 
RAVC versus 41·4 per 1000 person-years (21·5–61·2) in 
the clusters that received RACD only (table 3). The 
cumulative incidences of malaria in the intervention 
clusters reached lower weekly incidence peaks compared 
with the control clusters (rfMDA vs RACD, RAVC vs 
no RAVC, and rfMDA plus RAVC vs RACD only; 
appendix p 13). The crude IRR for rfMDA versus RACD 
was 0·82 (95% CI 0·26–1·37), for RAVC versus no 
RAVC was 0·78 (0·26–1·30), and for rfMDA plus RAVC 
versus RACD only was 0·62 (0·24–1·59). The adjusted 
IRR (aIRR) for rfMDA versus RACD was 0·52 
(0·16–0·88), for RAVC versus no RAVC was 0·48 
(0·16–0·80), and for rfMDA plus RAVC versus RACD 
only was 0·26 (0·10–0·68; table 3). In the individual-
level analysis of time-to-inci dent malaria, crude and 
adjusted hazard ratios were consistent with those of the 
IRRs (appendix p 14), and the proportion of individuals 
who remained free of malaria was higher in the 
intervention clusters compared with their respective 
control clusters (appendix p 15). There was no evidence 
that rfMDA modified the effect of RAVC on the 
incidence of malaria, and vice versa.
Compared with individuals who received the control 
interventions (RACD, no RAVC, or RACD only), the 
prevalence of malaria was lower in those that received 
the study interventions (rfMDA, RAVC, or rfMDA plus 
RAVC; table 4), particularly for rfMDA plus RAVC versus 
RACD only (prevalence of 1·75% [95% CI 0·99–3·09] vs 
3·70% [2·39–5·69], p=0·04). Crude and adjusted malaria 
prevalence ratios (aPRs) were consistent with the inci-
dence results, with an aPR of 0·59 (95% CI 0·21–0·98) 
for rfMDA versus RACD, 0·36 (0·13–0·59) for RAVC 
versus no RAVC, and 0·16 (0·05–0·55) for rfMDA plus 
RAVC versus RACD only (table 4). There was evidence 
that rfMDA and RAVC acted synergis ti cally to reduce the 
prevalence of malaria (interaction coefficient 0·17 [95% CI 
0·04–0·65], p=0·009).
In the adjusted models, baseline incidence and proxi-
mity to co-interventions administered by the Namibia 
Ministry of Health and Social Services showed a strong 
positive association with the incidence and prevalence of 
malaria (appendix p 16). Negative associations between 
target popu lation coverage and incidence, and between 
response time and prevalence, were observed. A higher 
baseline incidence in the intervention clusters compared 
with the control clusters, as well as imbalances in 
implementation factors, were drivers of the differences 
between the crude and adjusted point estimates 
(appendix pp 16–17).
Artemether-lumefantrine adherence was 100% (n=368) 
in individuals who still had their blister packs at follow-
up pill counts. Among individuals without their blister 
packs (n=316), all but one reported full adherence to 
artemether-lumefantrine treatment.
No serious adverse events were reported. Of 23 non-
serious adverse events reported in 18 individuals, 
19 (83%) were mild (grade 1), and four (17%) were 
moderate (grade 2). 17 (74%) of 23 adverse events were 
actively detected at follow-up visits. The number of 
reported adverse events and the number of adverse 
events by study arm are tabulated in the appendix (p 18). 






p value Incidence rate ratio 
(95% CI)* 
p value Adjusted incidence 
rate ratio (95% CI)†‡
p value
Human reservoir
RACD 27 38·3 (23·0–53·6) 0·26 1 (reference) 0·51 1 (reference) 0·009
rfMDA 28 30·8 (12·8–48·7) ·· 0·82 (0·26–1·37) ·· 0·52 (0·16–0·88) ··
Mosquito reservoir
No RAVC 27 38·9 (20·7–57·1) 0·23 1 (reference) 0·41 1 (reference) 0·002
RAVC 28 30·2 (15·0–45·5) ·· 0·78 (0·26–1·30) ·· 0·48 (0·16–0·80) ··
Human and mosquito reservoir
RACD only 13 41·4 (21·5–61·2) 0·11 1 (reference) 0·32 1 (reference) 0·006
rfMDA plus RAVC 14 25·0 (5·2–44·7) ·· 0·62 (0·24–1·59) ·· 0·26 (0·10–0·68) ··
RACD=reactive case detection. rfMDA=reactive focal mass drug administration. RAVC=reactive vector control. *Models include an interaction coefficient of 0·79 (95% CI 
0·21–2·94, p=0·72). †Adjusted for 2016 incidence of local cases, index case level and target population coverage for RACD or rfMDA, response time, and co-interventions by the 
Namibia Ministry of Health and Social Services (see appendix p 16 for full model outputs); RAVC coverage could not be included in the model because RAVC was not 
implemented in half of clusters in each arm (for the RACD vs rfMDA comparison), and RAVC was not implemented in all of the control clusters (for the RAVC vs no RAVC and 
rfMDA plus RAVC vs RACD only comparisons). ‡Models include interaction coefficient of 1·13 (95% CI 0·32–4·03, p=0·85).
Table 3: Cumulative incidence of locally acquired malaria (cluster-level analysis)
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the six-dose course of artemether-lumefantrine. The 
median time-to-resolution of symptoms was 1 day 
(maximum 7 days). Six adverse events were classified as 
probably related to artemether-lumefantrine, six were 
classified as possibly related to artemether-lumefantrine, 
and eleven were classified as unrelated to the inter-
ventions (including the RAVC intervention).
For insecticide susceptibility testing, fewer than 
100 larval specimens per insecticide type were available 
because heavy rains had washed away larvae in many 
locations. Bioassay tests among female adult mosquitoes 
showed 100% mortality to pirimiphos-methyl (n=90) and 
bendiocarb (n=46), 98% mortality to DDT (n=46), and 
71% mortality to deltamethrin (n=111). Deltamethrin-
resistant mosquitoes were identified morphologically 
as Anopheles gambiae complex, and PCR identified them 
as Anopheles arabiensis (66%, n=22) and Anopheles 
quadriannulatus (33%, n=11). No mutations in the voltage-
gated sodium channel (Vgsc-L104F and Vgsc-L1014S) 
conferring resistance to pyrethroids were present in the 
Anopheles arabiensis survivors.
Discussion
In this cluster-randomised trial we provide data on 
the effectiveness, safety, and operational feasibility of 
reactive focal drug and vector control interventions to 
reduce malaria transmission in a low malaria-endemic, 
P falciparum-dominant setting in Africa. We show that, 
when compared with their respective controls, rfMDA 
and RAVC each reduced the incidence of malaria by 
nearly 50% and had an additive effect when com bined, 
reducing incidence by almost 75%. End-of-season 
parasite prevalence confirmed these results, with a 
41% reduction in prevalence in clusters that received 
rfMDA compared with those that received RACD, and a 
64% reduction in prevalence in clusters that received 
RAVC compared with those that received no RAVC. 
There was evidence that rfMDA and RAVC had a 
synergistic effect on reducing malaria prevalence, with 
clusters that received rfMDA plus RAVC showing an 
84% reduc tion in prevalence compared with those 
that received RACD only. All interventions were safe 
and high community participation enabled more than 
80% coverage.
In Namibia and other low malaria-endemic countries, 
progress towards malaria elimination has faltered, 
despite the use of standard interventions, including 
symptomatic case management, preseason vector 
control with indoor residual spraying, and RACD.1,23 
RACD targets asymptomatic infections and hotspots of 
trans mission, but available point-of-care diagnostic tests 
are insufficiently sensitive and miss most infections.4,5,11 
MDA circumvents this limitation and is currently 
recommended for the elimination of malaria caused by 
P falciparum in areas with reliable access to case 
management, effective vector control, and low human 
migration.7 Uptake of MDA in countries or regions 
approaching malaria elimination has been slow, 
probably because of insufficient evidence and guidance 
regarding MDA for low malaria-endemic settings, and 
concerns about overtreatment and drug resistance. In 
most studies,8 MDA has been administered as a large-
scale blanket approach, which is impractical and 
wasteful when transmission is low and focal. The few 
trials9,10,29–32 of MDA administered on a smaller scale 
(ie, at a village level or to a group of households) have 
generally shown that this intervention is effective, but 
these studies are limited by small samples sizes and 
the inability to distinguish the effect of drug-based 
versus concurrently administered vector control interve-
ntions. Additionally, concerns about safety, acceptability, 
overtreatment, malaria importation, logistics, and 
resource limitations remain.8 rfMDA might address 
these issues by limiting antimalarials to individuals with 




p value Prevalence ratio 
(95% CI)*




RACD 2150 3·78% (2·85–5·00) 0·46 1 (reference) 0·92 1 (reference) 0·039
rfMDA 1932 3·16% (2·14–4·65) ·· 1·05 (0·03–2·07) ·· 0·59 (0·21–0·98) ··
Mosquito reservoir
No RAVC 2030 4·07% (2·92–5·64) 0·15 1 (reference) 0·13 1 (reference) <0·0001
RAVC 2052 2·92% (2·13–3·99) ·· 0·61 (0·10–1·12) ·· 0·36 (0·13–0·59) ··
Human and mosquito reservoir
RACD only 1016 3·70% (2·39–5·69) 0·04 1 (reference) 0·17 1 (reference) 0·004
rfMDA plus RAVC 918 1·75% (0·99–3·09) ·· 0·52 (0·20–1·32) ·· 0·16 (0·05–0·55) ··
RACD=reactive case detection. rfMDA=reactive focal mass drug administration. RAVC=reactive vector control. *Models include an interaction coefficient of 0·30 (95% CI 
0·06–1·43, p=0·13). †Adjusted for 2016 incidence of local cases, index case level and target population coverage for RACD or rfMDA, response time, and co-interventions by 
the Namibia Ministry of Health and Social Services (see appendix p 16 for full model outputs); RAVC coverage could not be included in the model because RAVC was not 
implemented in half of clusters in each arm (for the RACD vs rfMDA comparison), and RAVC was not implemented in all of the control clusters (for the RAVC vs no RAVC and 
rfMDA plus RAVC vs RACD only comparisons). ‡Models include an interaction coefficient of 0·17 (95% CI 0·04–0·65, p=0·009).
Table 4: Prevalence of quantitative PCR-detected infection
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Reactive focal indoor residual spraying with pirimiphos-
methyl was a novel strategy tested in this study, targeting 
the mosquito as a reservoir and transmitter of infections. 
In general, indoor residual spraying is resource intensive 
and pirimiphos-methyl is costly. However, as with rfMDA, 
we used a highly focal approach that builds on the existing 
RACD infrastructure. Reactive indoor residual spraying 
can compensate for incomplete or poorly applied 
spraying during the preseason routine indoor residual 
spraying. The use of an insecticide from a different 
chemical class to the one used in routine indoor residual 
spraying could slow the selection for insecticide resistance 
in the vector.18 Insecticide resistance to pyre throids and 
DDT has forced many countries to switch to new 
generation insecticides; however, despite being very 
effective, the high cost of new generation insecticides 
means that universal coverage of indoor residual spraying 
is unaffordable.33 Reactive focal approaches in an 
elimination context are therefore of particular interest.12
The results of our study suggest that both rfMDA and 
RAVC, alone and in combination, effectively decreased 
the incidence and prevalence of malaria. When com-
bined, rfMDA and RAVC were additive in reducing the 
incidence and prevalence of infection. In addition, the 
synergistic effects of these interventions on infection 
prevalence is consistent with other studies8,9 showing 
that MDA had maximal efficacy when combined with 
vector control strategies. Combining interventions could 
help to overcome incomplete coverage that occurs when 
interventions are administered alone. Targeting both 
human and vector parasite reservoirs could also prevent 
a cascade of subsequent transmission events originating 
from either reservoir.
Safety and operational factors, such as coverage, 
adherence, and acceptability are key when malaria 
interventions are directed at largely asymptomatic and 
uninfected individuals. Importantly, all interventions 
administered in our study were safe. A coverage of 
greater than 80% is generally recommended for MDA or 
vector control interventions to achieve community-level 
protection.8 In our study, intervention coverage (>80%) 
and adherence (100%) were high, and the number of 
individuals who refused the assigned interventions was 
low (<1%). High coverage and acceptability could have 
been due to effective community sensitisation activities 
before the study,10 ongoing engagement by staff during 
pharmacovigilance and follow-up visits, and high 
motivation for individuals to participate because of the 
perceived threat of malaria when there was a recent case 
in their neighbourhood.34
Our study has some limitations. First, the large differ-
ences in crude and adjusted incidence and prevalence 
estimates were due to an imbalance of factors in the study 
arms that were associated with the trial outcomes. The 
incidence of malaria in 2016 was higher in the clusters 
that received the study interventions than those that 
received the control interventions; however, it was not 
included in the restricted randomisation, as 2016 was 
mistakenly considered an anomalous year when compared 
with the previous 5 years of low transmission. There 
was also an imbalance in intervention implementation 
factors across the three comparison arms, particularly 
with regards to interventions administered by the Namibia 
Ministry of Health and Social Services that were beyond 
the control of the study team. However, as these factors 
were measured during the trial, they could be accounted 
for in multivariable models, which provided more accurate 
estimates of the intervention effects. Second, median 
response times were long (2 weeks) and could have 
limited the effectiveness of the interventions. Third, the 
absence of buffer zones could have resulted in an 
underestimation of effect sizes because of spillover 
between study arms. Fourth, field implementation was 
not blinded; however, incidence and prevalence estimates 
were unlikely to have been biased as, generally, all patients 
presenting with fever received malaria testing, and 
laboratory assays in the cross-sectional survey were done 
blinded. Finally, the incidence of malaria in 2016 and 2017 
was higher than originally anticipated. The resultant 
operational challenges in 2016 led to a shortened study 
period of just 1 year instead of 2 years. During the 2017 
study year, a higher than anticipated proportion of the 
total population received the assigned intervention 
(approximately half for rfMDA and RACD, and a third 
for RAVC). The interventions were nonetheless reactive 
and focally administered, and thus tailored and varied 
over time and location. Considering the high-resource 
requirements (ie, staff, infrastructure, and transport), real-
world adoption of rfMDA or RAVC, or both, will probably 
require lower trans mission intensity (ie, fewer index 
cases to respond to) than what was encountered during 
our study. A cost-effectiveness analysis will be reported 
elsewhere. Future studies should incorporate longer 
implementation and follow-up periods.
Using an antimalarial drug with a longer half-life 
and thereby a longer prophylactic effect (eg, dihydro-
artemisinin-piperaquine), or using an additional drug 
that inhibits transmission (eg, a single dose of 
primaquine or ivermectin), might have improved the 
effectiveness of rfMDA.10,35 The effectiveness of RAVC 
could have been limited by residual transmission of 
malaria due to the opportunistic feeding and outdoor 
biting of Anopheles arabiensis. However, the observed 
effect sizes with indoor residual spraying of pirimiphos-
methyl were large, and there was existing infrastruc-
ture and community famil iarity with the intervention. 
In other settings, vector control strategies that target 
residual malaria transmission as they become available 
could be considered.36
To our knowledge, our trial is the first to evaluate 
reactive focal malaria intervention strategies. The effect 
sizes in the adjusted analyses were substantial; compared 
with clusters that received RACD only, those that received 
rfMDA plus RAVC showed a 74% reduction in the 
Articles
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incidence and an 84% reduction in the prevalence of 
malaria. No existing tools, including insecticide-treated 
bednets, indoor residual spraying, or the new RTS,S/AS01 
vaccine have shown such large protective efficacies.37,38 
The factorial design of our study enabled two different 
interventions to be assessed, both individually and 
combined, unlike previous studies.8–10
In summary, our study shows that, reactive targeting of 
parasites in humans and vectors after an index case is 
effective, safe, and acceptable in a low-transmission 
setting. In regions where standard approaches for using 
antimalarials and vector control strategies have been 
used for many years without achieving malaria elimi-
nation, more effective deployment strategies, such as 
those evaluated in our study, should be considered for 
implementation.
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